Late complications of hematopoietic stem cell transplantation

Hematopoietic Stem Cell Transplantation

Volumn , Issue , 2000, Pages 413-433

  Kansu, Emin ^a   Sullivan, Keith M ^b  

^a HACETTEPE UNIVERSITY   (Turkey)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884911675     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (84)

1. Agosti JM, Sprenger JD, Lum LG, Witherspoon RP, Storb R, Henderson WR. Transfer of allergenspecific IgE mediated hypersensitivity with allogeneic bone-marrow transplantation. N Engl J Med 1988; 319: 1623-1628.
2. Armitage JO. Research potential of the ABMTR Database. Autologous Blood and Marrow Transplant Registry-North America 1994; 1: 2.
3. Atkinson K. Chronic graft-versus-host disease (review). Bone Marrow Transplant 1990; 5: 69-82.
4. Atkinson K, Storb R, Prentice RL, Weiden PL, Witherspoon RP, Sullivan KM, Noel D, Thomas ED. Analysis of late infections in 89 long-term survivors of bone marrow transplantation. Blood 1979; 53: 720-731.
5. Atkinson K, Farewell V, Storb R, Tsoi M-S, Sullivan KM, Witherspoon RP, Fefer A, Clift R, Goodell B, Thomas ED. Analysis of late infections after human bone marrow transplantation: role of genotypic nonidentity between marrow donor and recipient and of non-specific suppressor cells in patients with chronic graft-versus-host disease. Blood 1982; 60: 714-720.
6. Atkinson K, Biggs J, Darveniza P, Boland J, Concannon A, Dodds A. Cyclosporine-associated central nervous system toxicity after allogeneic bone marrow transplantation. Transplantation 1984; 38: 34-37.
7. Aucouturier P, Barra A, Intrator L, Cordonnier C, Schulz D, Duarte F, Vernant J-P, Oreud’homme J-L. Long lasting IgG subclass and anti-bacterial polysaccharide antibody deficiency after allogeneic bone marrow transplantation. Blood 1987; 70: 779-785.
8. Bearman SI, Appelbaum FR, Buckner CD, Peterson FB, Fisher LD, Clift RA, Thomas ED. Regimenrelated toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568.
9. Benyunes MC, Sullivan KM, Deeg HJ, Mori M, Meyer W, Fisher L, Bensinger W, Jack MK, Hicks J, Witherspoon R, Buckner CD, Hansen JA, Appelbaum FR, Storb R. Cataracts after bone marrow transplantation: long-term follow-up of adults treated with fractionated total body irradiation. Int J Radiat Oncol Biol Phys 1995; 32: 661-670.
10. Bush NE, Haberman M, Donaldson G, Sullivan KM. Quality of life of 125 adults surviving 6-18 years after bone marrow transplantation. Soc Sci Med 1995; 40: 479-490.
11. Chao NJ, Tierney DK, Bloom JR, Long GD, Barr TA, Stallbaum BA, Wong RM, Negrin RS, Horning SJ, Blume KG. Dynamic assessment of quality of life after autologous bone marrow transplantation. Blood 1992; 80: 825-830.
12. Clark JG, Schwartz DA, Flournoy N, Sullivan KM, Crawford SW, Thomas ED. Risk factors for airflow obstruction in recipients of bone marrow transplants. Ann Intern Med 1987; 107: 648-656.
13. Clark JG, Crawford SW, Madtes DK, Sullivan KM. Obstructive lung disease after allogeneic marrow transplantation. Ann Intern Med 1989; 111: 368-376.
14. Clift R, Goldman J, Gratwohl A, Horowitz M. Proposals for standardized reporting of results of bone marrow transplantation for leukemia. Bone Marrow Transplant 1989; 4: 445-448.
15. Curtis RE, Rowlings PA, Deeg HJ, Shriner DA, Socie G, Travis LB, Horowitz MM, Witherspoon RP, Hoover RN, Sobocinski KA, Fraumeni JF, Boice JD. Solid cancers after bone marrow transplantation. N Engl J Med 1997; 336: 897-904.
16. Deeg HJ, Socie G, Schoch G, Henry-Amar M, Witherspoon RP, Devergie A, Sullivan KM, Gluckman E, Storb R. Malignancies after marrow transplantation for aplastic anemia and Fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood 1996; 87: 386-392.
17. Flowers ME, Sullivan KM. Pre-admission procedures, marrow transplant hospitalization, and posttransplant outpatient monitoring. In: Atkinson K, ed. Textbook on Bone Marrow Transplantation, London: Cambridge University Press, 1992: 75-86.
18. Fried RH, Murakami CS, Fisher LD, Wilson RA, Sullivan KM, McDonald GB. Ursodeoxycholic acid treatment of refractory chronic graft-versus-host of the liver. Ann Intern Med 1992; 116: 624-629.
19. Heimpel H, Arnold R, Hetzel WD, Hueske D, Kreuser ED, Wirthenson EF, Voss AC, Slanina J. Gonadal function after bone marrow transplantation in adult male and female patients. Bone Marrow Transplant 1991; 8(suppl 1): 21-24.
20. Higano CS, Raskind WH, Singer JW. Use of alpha-interferon for treatment of relapse of chronic myelogenous leukemia in chronic phase after allogeneic bone marrow transplantation. Blood 1992; 80: 1437-1442.
21. Hinterberger-Fisher M, Kier P, Kalhs P, Marosi C, Geissler K, Schwarzinger I, Pabinger I, Huber J, Spona J, Kolbabek H, Koren H, Muller G, Hawliczek R, Lechner K, Hayek-Rosenmayr A, Hinterberger W. Fertility, pregnancies and offspring complications after bone marrow transplantation. Bone Marrow Transplant 1991; 7: 5-9.
22. Janin A, Socie G, Devergie A, Aractingi S, Esperou H, Verola O, Gluckman E. Fasciitis in chronic graft-versus-host disease. Ann Intern Med 1994; 120: 993-998.
23. Jones RB, Shpall EJ. Dissemination and commercialization of hematopoietic progenitor cell transplantation (editorial). Hematotherapy 1994; 3: 93-94.
24. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM, ed. Evaluation of Chemotherapeutic Agents. New York: Columbia Press, 1949: 199-205.
25. Kelly PJ, Atkinson K, Ward RL, Sambrook PN, Biggs JC, Eisman JC. Reduced bone mineral density in men and women with allogeneic bone marrow transplantation. Transplantation 1990; 50: 881-883.
26. Kernan NA, Bartsch G, Ash RC, Beatty PG, Champlin R, Filipovich A, Gajewski J, Hansen JA, Henslee-Downey J, McCullough J, McGlave P, Perkins HA, Phillips GL, Sanders J, Stroncek D, Thomas ED, Blume KG. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 1993; 328: 593-602.
27. Kolb HJ, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G, Heim M, Wilmanns W. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462-2465.
28. Kurtzberg J, Laughlin M, Graham ML, Smith C, Olson JF, Halperin EC, Ciocci G, Carrier C, Stevens CE, Rubinstein P. Placental blood as a source of hematopoietic stem cell for transplantation into unrelated recipients. N Engl J Med 1996; 335: 157-166.
29. Lansky SB, List MA, Lansky LL, Ritter-Sterr C, Miller DR. The measurement of performance in childhood cancer patients. Cancer 1987; 60: 1651-1656.
30. Ljungman P, Fridell E, Lonnqvist B, Bolme P, Bottiger M, Gahrton G, Linde A, Ringden O, Wahren B. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine. J Infect Dis 1989; 159: 610-615.
31. Locksley RM, Flournoy N, Sullivan KM, Meyers JD. Infection with varicella-zoster virus after marrow transplantation. J Infect Dis 1985; 152: 1172-1181.
32. Lucarelli G, Galimbeti M, Pochi P, Angelucci E, Baronciani D, Giardini C, Andreani M, Agostinelli F, Albertini F, Clift RA. Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. N Engl J Med 1993; 329: 840-844.
33. Mortimer J, Blinder MA, Schulman S, Appelbaum FR, Buckner CD, Clift RA, Sanders JE, Storb R, Thomas ED. Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy. J Clin Oncol 1989; 7: 50-57.
34. Morton AJ, Anasetti C, Gooley T, Flowers MED, Deeg HJ, Hansen JA, Martin PJ, Sullivan KM. Chronic graft-versus-host disease (GVHD) following unrelated donor transplantation (abstr). Blood 1997a; 90: 590a.
35. Morton AJ, Gooley T, Hansen JA, Appelbaum FR, Bjerke JW, Clift R, Martin PJ, Petersdorf EW, Sanders JE, Storb R, Sullivan KM. Impact of pretransplant interferon-alpha on outcome of unrelated donor marrow transplants for chronic myeloid leukemia (CML) in first chronic phase (abstr). Blood 1997b; 90: 105a.
36. Nash RA, Furlong T, Storb R, Anasetti C, Appelbaum FR, Deeg HJ, Doney K, Martin R, Witherspoon R, Sullivan KM. Mycophenolate mofetil (MMF) as salvage treatment for graft-versushost disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT): safety analysis (abstr). Blood 1997; 90(suppl. 1): 459a.
37. Nims JW. Late effects of bone marrow transplantation: a nursing perspective. In: Kasprisin CA, ed. Bone Marrow Transplantation: A Nursing Perspective. Arlington, VA: American Association of Blood Banks, 1990: 45-57.
38. Olsen GA, Gockerman JP, Bast RC Jr, Borowitz M, Peters WP. Altered immunologic reconstitution after standard-dose chemotherapy or high-dose chemotherapy with autologous bone-marrow support. Transplantation 1988; 46: 57-60.
39. Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH, Castro-Malaspina H, Childs BH, Gillio AP, Small TN, Young JW, Kernan NA, O’Reilly RJ. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994; 330: 1185-1191.
40. Peters WP, Ross M, Vredenburgh JJ, Hussein A, Rubin P, Dukelow K, Cavanaugh C, Beauvais R, Kasprzak S. The use of intensive clinic support to permit outpatient autologous bone marrow transplantation for breast cancer. Semin Oncol 1994; 21(Suppl 7): 25-31.
41. Radich JP, Sanders JE, Buckner CD, Martin PJ, Peterson FB, Bensinger W, McDonald GB, Moro M, Schoch G, Hansen JA. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. J Clin Oncol 1993; 11: 304-313.
42. Radich JP, Gehly G, Gooley T, Bryant E, Clift RA, Collins S, Edmands S, Kirk J, Lee A, Kessler P, Schoch G, Buckner CD, Sullivan KM, Appelbaum FR, Thomas ED. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood 1995; 85: 2632-2638.
43. Rowe JM, Ciobanu N, Ascensao J, Stadtmauer EA, Weiner RS, Schenkein DP, McGlave P, Lazarus HM, ECOG. Recommended guidelines for the management of autologous and allogeneic bone marrow transplantation: a report from the Eastern Cooperative Oncology Group (ECOG). Ann Intern Med 1994; 120: 143-158.
44. Sanders JE. Growth and development after bone marrow transplantation. In: Forman FSJ, Blume KG, Thomas ED, eds. Bone Marrow Transplantation. Boston: Blackwell, 1994: 527-537.
45. Sanders JE, Buckner CD, Leonard JM, Sullivan KM, Witherspoon RP, Deeg HJ, Storb R, Thomas ED. Late effects on gonadal function of cyclophosphamide total-body irradiation, and marrow transplantation. Transplantation 1983; 36: 252-255.
46. Sanders JE, Buckner CD, Amos D, Levy W, Appelbaum FR, Doney K, Storb R, Sullivan KM, Witherspoon RP, Thomas ED. Ovarian function following marrow transplantation for aplastic anemia or leukemia. J Clin Oncol 1988; 6: 813-818.
47. Sanders JE, and the Seattle Transplant Team. The impact of marrow transplant preparative regimens on subsequent growth and development. Semin Hematol 1991; 28: 244-249.
48. Sanders JE, Hawley J, Levy W, Gooley T, Buckner CD, Deeg HJ, Doney K, Storb R, Sullivan KM, Witherspoon R, Appelbaum FR. Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total body irradiation and bone marrow transplantation. Blood 1996; 87: 3045-3052.
49. Schimpff SC, Diggs CH, Wiswell JG, Salvatore PC, Wiernik PH. Radiation-related thyroid dysfunction: Implications for the treatment of Hodgkin’s disease. Ann Intern Med 1980; 92: 91-98.
50. Schmidt GM, Niland JC, Forman SJ, Fonbuena PP, Dagis AC, Grant MM, Ferrell BR, Barr TA, Stallbaum BA, Chao NJ, Blume KG. Extended follow-up of 212 long-term allogeneic bone marrow transplant survivors. Transplantation 1993; 55: 551-557.
51. Schubert MA, Sullivan KM, Schubert MM, Nims J, Hansen M, Sanders JE, O’Quigley J, Witherspoon RP, Buckner CD, Storb R, and Thomas ED. Gynecological abnormalities following allogeneic bone marrow transplantation. Bone Marrow Transplant 1990; 5: 425-430.
52. Schuchter LM, Wingard JR, Piantadosi S, Burns WH, Santos GW, Saral R. Herpes zoster infection after autologous bone marrow transplantation. Blood 1989; 74: 1424-1427.
53. Sklar CA, Kim TH, Ramsay NK. Thyroid dysfunction among long-term survivors of bone-marrow transplantation. Am J Med 1982; 73: 688-694.
54. Socie G, Henry-Amar M, Bacigalupo A, Hows J, Tichelli A, Ljungman P, McCann SR, Frickhofen N, Veer-Kirthof EV, Gluckman E. Malignant tumors occurring after treatment of aplastic anemia. N Engl J Med 1993; 329: 1152-1157.
55. Socie G, Selimi F, Sedel L, Frija J, Devergie A, Esperou-Bourdeau H, Ribaud P, Gluckman E. Avascular necrosis of bone after allogeneic bone marrow transplantation: clinical findings, incidence and risk factors. Br J Haematol 1994; 86: 624-628.
56. Stern JM, Chesnut CH, Bruemmer B, Sullivan KM, Lenssen PS, Aker SN, Sanders J. Bone density loss during treatment of chronic GVHD. Bone Marrow Transplant 1996; 17: 395-400.
57. Storek J, Gooley T, Siadak M, Bensinger WI, Maloney DG, Chauncey TR, Flowers M, Sullivan KM, Witherspoon RP, Rowley SD, Hansen JA, Storb R, Appelbaum FR. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood 1997; 90: 4705-4709.
58. Sullivan KM. Long-term follow-up and quality of life after hematopoietic stem cell transplantation. J Rheumatol 1997; 24(suppl 48): 46-52.
59. Sullivan KM, Furst DE. The evolving role of blood and marrow transplantation for the treatment of autoimmune diseases. J Rheumatol 1997; 24(suppl 48): 1-4.
60. Sullivan KM, Siadak M. Stem cell transplantation. In: Johnson FE, Virgo KS, Edge SB, et al., eds. Cancer Patient Follow-Up. St. Louis: Mosby-Yearbook, 1997: 490-501.
61. Sullivan KM, Shulman HM, Storb R, Weiden PL, Witherspoon RP, McDonald GB, Schubert MM, Atkinson K, Thomas ED. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981; 57: 267-276.
62. Sullivan KM, Storb R, Shulman HM, Shaw C-M, Spence A, Beckham C, Clift RA, Buckner D, Stewart P, Thomas ED. Immediate and delayed neurotoxicity after mechlorethamine preparation for bone marrow transplantation. Ann Intern Med 1982; 27: 182-189.
63. Sullivan KM, Meyers JD, Flournoy N, Storb R, Thomas ED. Early and late interstitial pneumonia following human bone marrow transplantation. Int J Cell Cloning 1986; 4: 107-121.
64. Sullivan KM, Witherspoon RP, Storb R, Weiden P, Flournoy N, Dahlberg S, Deeg JH, Sanders JE, Doney KC, Appelbaum FR, McGuffin R, McDonald GB, Meyers J, Schubert MM, Gauvreau J, Shulman HM, Sale GE, Anasetti C, Loughran TP, Strom S, Nims J, Thomas ED. Prednisone and azathioprine compared with prednisone and placebo for the treatment of chronic graftversus-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood 1988; 72: 546-554.
65. Sullivan KM, Storb R, Buckner CD, Fefer A, Fisher L, Weiden PL, Witherspoon RP, Appelbaum FR, Banaji M, Hansen J, Martin P, Sanders JE, Singer J, Thomas ED. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med 1989; 320: 828-834.
66. Sullivan KM, Siadak MF, Witherspoon RW. Cyclosporine treatment of chronic graft-versus-host disease following allogeneic bone marrow transplantation. Transplant Proc 1990; 22: 1336-1338.
67. Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S, Erickson K, Flowers M, Hansen J, Loughran T, Martin P, Matthews D, Petersdorf E, Radich J, Riddell S, Rovira D, Sanders J, Schuening F, Siadak M, Storb R, Witherspoon R. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28: 250-259.
68. Sullivan KM, Mori M, Sanders JE, Siadak M, Witherspoon RP, Anasetti C, Appelbaum FR, Bensinger W, Bowden R, Buckner CD, Clark J, Crawford S, Deeg HJ, Doney K, Flowers M, Hansen J, Loughran T, Martin P, McDonald G, Pepe M, Petersen FB, Schuening F, Stewart P, Storb R. Late complications of allogeneic and autologous marrow transplantation (review). Bone Marrow Transplant 1992; 10: 127-134.
69. Sullivan KM. Graft-versus-host disease. In: Forman SJ, Blume KG, Thomas ED, eds. Bone Marrow Transplantation. Boston: Blackwell, 1994: 339-362.
70. Sullivan KM, Storek J, Kopecky KJ, Jocom J, Longton G, Flowers M, Siadak M, Nims J, Witherspoon RP, Anasetti C, Appelbaum F, Bowden RA, Buckner D, Crawford SW, Deeg HJ, Hansen JA, McDonald GB, Sanders JE, Storb R. A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-versus-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery. Biol Blood Bone Marrow Transplant 1996; 2: 44-53.
71. Syrjala KL, Chapko MK, Vitaliano PP, Cummings C, Sullivan KM. Recovery after allogeneic marrow transplantation: prospective study of predictors of long-term physical and psychosocial functioning. Bone Marrow Transplant 1993; 11: 319-327.
72. Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, weight velocity, and stages of puberty. Arch Dis Child 1976; 51: 170-179.
73. Thompson CB, Sanders JE, Flournoy N, Buckner CD, Thomas ED. The risks of central nervous system relapse and leukoencephalopathy in patients receiving marrow transplants for acute leukemia. Blood 1986; 67: 195-199.
74. Thurston GM, Hayden DL, Burrows P, Clark JI, Taret VG, Kandel J, Courogen M, Peetermans JA, Dowen MS, Miller D, Sullivan KM, Storb R, Stern H, Benedek GB. Quasielastic light scattering study of the living human lens as a function of age. Curr Eye Res 1997; 16: 197-207.
75. Vogelsang GB, Farmer ER, Hess AD, Altamonte V, Beschorner WE, Jabs DA, Corio RL, Levin LS, Colvin OM, Wingard JR, Santos GW. Thalidomide for the treatment of chronic graftversus-host disease. N Engl J Med 1992; 326: 1055-1058.
76. Walters MC, Patience M, Leisenring W, Eckman JR, Scott JP, Mentzer WC, Davies SC, Ohene-Frempong K, Bernaudin F, Matthews DC, Storb R, Sullivan KM. Bone marrow transplantation for sickle cell disease. N Engl J Med 1996; 335: 369-376.
77. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED, Seattle Marrow Transplant Team. Anti-leukemic effect of chronic graft-versus-host disease. N Engl J Med 1981; 304: 1529-1533.
78. Wingard JR, Piantadosi S, Vogelsang GB, Farmer ER, Jabs DA, Levin LS, Beschorner WE, Cahill RA, Miller DF, Harrison D, Saral R, Santos GW. Predictors of death from chronic graft-versushost disease after bone marrow transplantation. Blood 1988; 74: 1428-1435.
79. Wingard JR, Curbow B, Baker F, Piantadosi S. Health, functional status, and employment of adult survivors of bone marrow transplantation. Ann Intern Med 1991; 114: 113-118.
80. Wingard JR, Plotnick LP, Freemer CS, Zahurak M, Piantadosi S, Miller DF, Huibert M, Vriesendorp HM, Yeager AM, Santos GW. Growth in children after bone marrow transplantation: busulfan plus cyclophosphamide versus cyclophosphamide plus total body irradiation. Blood 1992; 79: 1068-1073.
81. Winston DJ, Schiffman G, Wang DC, Feig SA, Lin C-H, Marso EL, Ho WG, Young LS, Gale RP. Pneumococcal infections after human bone marrow transplantation. Ann Intern Med 1979; 91: 835-841.
82. Witherspoon RP, Lum LG, Storb R. Immunologic reconstitution after human marrow grafting. Semin Hematol 1984; 21: 2-10.
83. Witherspoon RP, Fisher LD, Schoch G, Martin P, Sullivan KM, Sanders J, Deeg HJ, Maloney K, Thomas D, Storb R, Thomas ED. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med 1989; 321: 784-789.
84. Witherspoon RP, Storb R, Pepe M, Longton G, Sullivan KM. Cumulative incidence of secondary solid malignant tumors in aplastic anemia patients given marrow grafts after conditioning with chemotherapy alone. Blood 1992; 79: 289-292.